Insight Molecular Diagnostics IMDX Estimates

NASDAQ IMDX
$4.27 -0.03 (-0.70%)
As of: Aug 27, 2026 · 3:59 PM EDT
Analyst Estimates

Insight Molecular Diagnostics Inc. Revenue Estimates

Periods 23
Next Period Q2 26
Consensus 417,950.31

Analysts expect Insight Molecular Diagnostics Inc. to report revenue of 417,950.31 for Q2 26, against a range of 399,657.04 to 436,243.58. The most recent reported quarter, Q1 26, came in at 32,000.00, a 86.7% miss against the 240,119.41 consensus.

Metric Q2 24Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28Q1 29Q2 29Q3 29Q4 29
Reported (Actual) 104,000.00115,000.001.49 M2.14 M518,000.00260,000.001.14 M32,000.00--------
High Estimate 329,061.44206,078.35116,903.70138,797.96309,661.44292,638.64300,725.93250,121.58436,243.58540,218.941.17 M982,484.312.29 M2.09 M5.31 M2.79 M
Low Estimate 283,978.48170,736.51100,377.30126,674.88290,232.66239,665.34250,843.13230,117.24399,657.04505,303.721.01 M880,433.671.99 M1.74 M4.66 M2.42 M
Consensus Estimate 306,519.96188,407.43108,640.50132,736.42299,947.05266,151.99275,784.53240,119.41417,950.31522,761.331.09 M931,458.992.14 M1.92 M4.99 M2.61 M
Analyst Estimates

Insight Molecular Diagnostics Inc. Earnings Per Share (EPS) Estimates

Periods 23
Next Period Q2 26
Consensus -0.23

Analysts expect Insight Molecular Diagnostics Inc. to report earnings per share of -0.23 for Q2 26, against a range of -0.24 to -0.22. The most recent reported quarter, Q1 26, came in at -0.12, a 50.0% beat against the -0.24 consensus.

Metric Q2 24Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28Q1 29Q2 29Q3 29Q4 29
Reported (Actual) -0.38-0.40-1.93-0.26-0.30-0.34-0.72-0.12--------
High Estimate -0.49-0.40-0.34-0.24-0.20-0.20-0.23-0.23-0.22-0.22-0.18-0.20-0.22-0.20-0.290.00
Low Estimate -0.59-0.44-0.40-0.28-0.22-0.24-0.27-0.25-0.24-0.24-0.22-0.24-0.26-0.22-0.330.00
Consensus Estimate -0.54-0.42-0.37-0.26-0.21-0.22-0.25-0.24-0.23-0.23-0.20-0.22-0.24-0.21-0.310.00